Keywords: xenoport, exercises, option, co-market, solzira, usa, gsk
XenoPort exercises option to co-market Solzira in USA with GSK
Article | 16 April 2009
US drugmaker XenoPort has exercised the option contained in its deal with UK drug major GlaxoSmithKline to co-promote and share ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
